NUPR1 and glioblastoma: Opportunities to trial TFP for GBM may be at the onset of recurrent disease, where average NUPR1 expression is higher, or alternatively perioperatively in newly diagnosed patients with GBM, when residual tumor cells at the margin of the resection cavity are acutely reexposed to CSF.